Press Releases

Topics:
  TITLE DATE  
 
 

Nymox Reports Additional Positive Results From Completed Fexapotide BPH Phase 3 Studies Showing Significant Early Response and First-Line Efficacy

2016-11-29

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation is pleased to announce that new Phase 3 prospective randomized clinical trial results have confirmed that patients who received fexapotide as their initial treatment for BPH (prostate enlargement) had superior efficacy results as early as 10 days compared to control patients who received placebo or who had prior history of other BPH medical treatments.

 
 
 

Nymox Reports Successful New Phase 3 Long-Term Fexapotide Repeat Injection BPH Trial Results: Lasting Symptomatic Improvement Up To 6 Years After Single Repeated Treatment

2016-10-11

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation is pleased to announce successful new study results from the long-term repeated injection group from the U.S. Phase 3 trials for fexapotide, the Company's lead compound in late stage development for enlarged prostate (BPH) and for localized prostate cancer.

 
 
 

Nymox's New Phase 3 Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show

2016-08-29

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation lead drug fexapotide which has been in development for over a decade and which has been tested by expert clinical trial investigative teams in over 70 distinguished clinical trial centers...

 
 
 

Nymox Reports Successful New Long-Term Fexapotide Placebo Crossover Study Results: Major Reduction in Incidence of Surgery

2016-08-24

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation is pleased to announce successful new study results from the long-term blinded placebo crossover group from the U.S. Phase 3 trials for fexapotide, the Company's lead compound in late stage development for enlarged prostate (BPH) and for localized prostate cancer.

 
 
 

Nymox Announces Private Placements of $2.24 Million

2016-08-17

 
 
Topic:  Financial
 
 

Nymox Pharmaceutical Corporation is pleased to announce that it has recently closed private placements and other investments in the Company for a total of $2.24 million.

 
 
 

Nymox Announces Prostate Drug Progress

2016-08-11

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation is pleased to announce major progress in the evidence for the safety and efficacy of fexapotide, the Company's Phase 3 drug in the final stages of development for prostate enlargement (BPH) and for low grade prostate cancer.

 
 
 

Nymox Reports Long-Term Prostate Cancer Results in 7 Year Prospective Study of 995 U.S. Middle-Aged and Elderly Men Without Cancer

2016-06-22

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation announced today results from the Company's 7 year prospective placebo controlled double blind studies of treatment of 995 U.S. men with the Company's lead drug fexapotide.

 
 
 

Nymox Announces Prostate Cancer Clinical Trial Results From Completed 18 Month Endpoint Study

2016-02-09

 
 
Topic:  R&D: Cancer Treatments
 
 

Nymox Pharmaceutical Corporation today announced results from the completion of the Company's U.S. 40 month (18 month outcomes) localized prostate cancer Phase 2 NX03-0040 clinical trial of fexapotide triflutate (NX-1207).

 
 
 

Nymox Announces Additional $2.1 Million Equity Financing

2016-02-04

 
 
Topic:  Financial
 
 

Nymox Pharmaceutical Corporation announced today private placement equity investment of US$2.1 Million.

 
 
 

Nymox Files Current Financial Statements

2015-12-31

 
 
Topic:  Financial
 
 

Nymox Pharmaceutical Corporation is pleased to announce that today the Company has filed its third quarter 2015 and restated second quarter 2015 financial statements.

 
  Total   367   Records   First   Previous   1 of 37   Next   Last      Go